|
1
|
Yuen KS, Ye ZW, Fung SY, Chan CP and Jin
DY: SARS-CoV-2 and COVID-19: The most important research questions.
Cell Biosci. 10:402020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kostoff RN: Combining Tactical and
Strategic Treatments for COVID-19. Georgia Institute of Technology;
2020, http://hdl.handle.net/1853/62523
Accessed March 23 2020.
|
|
3
|
Hashem MM, Abo-El-Sooud K, Abd-Elhakim YM,
Badr YA, El-Metwally AE and Bahy-El-Dien A: The long-term oral
exposure to titanium dioxide impaired immune functions and
triggered cytotoxic and genotoxic impacts in rats. J Trace Elem Med
Biol. 60:1264732020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torres M, Carranza C, Sarkar S, Gonzalez
Y, Osornio Vargas A, Black K, Meng Q, Quintana-Belmares R,
Hernandez M, Angeles Garcia JJF, et al: Urban airborne particle
exposure impairs human lung and blood Mycobacterium tuberculosis
immunity. Thorax. 74:675–683. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goumenou M, Sarigiannis D, Tsatsakis A,
Anesti O, Docea AO, Petrakis D, Tsoukalas D, Kostoff R, Rakitskii
V, Spandidos DA, et al: COVID-19 in Northern Italy: An integrative
overview of factors possibly influencing the sharp increase of the
outbreak (Review). Mol Med Rep. 22:20–32. 2020.PubMed/NCBI
|
|
6
|
Omran GA: Hematological and immunological
impairment following in-utero and postnatal exposure to aluminum
sulfate in female offspring of albino rats. Immunopharmacol
Immunotoxicol. 41:40–47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reid N, Moritz KM and Akison LK: Adverse
health outcomes associated with fetal alcohol exposure: A
systematic review focused on immune-related outcomes. Pediatr
Allergy Immunol. 30:698–707. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engin AB, Nikitovic D, Neagu M,
Henrich-Noack P, Docea AO, Shtilman MI, Golokhvast K and Tsatsakis
AM: Mechanistic understanding of nanoparticles' interactions with
extracellular matrix: The cell and immune system. Part Fibre
Toxicol. 14:222017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Delfosse VC, Tasat DR and Gioffré AK: In
vivo short-term exposure to residual oil fly ash impairs pulmonary
innate immune response against environmental mycobacterium
infection. Environ Toxicol. 30:589–596. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsatsakis A, Docea AO, Constantin C,
Calina D, Zlatian O, Nikolouzakis TK, Stivaktakis PD, Kalogeraki A,
Liesivuori J, Tzanakakis G, et al: Genotoxic, cytotoxic, and
cytopathological effects in rats exposed for 18 months to a mixture
of 13 chemicals in doses below NOAEL levels. Toxicol Lett.
316:154–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Docea AO, Calina D, Goumenou M, Neagu M,
Gofita E and Tsatsakis A: Study design for the determination of
toxicity from long-term-low-dose exposure to complex mixtures of
pesticides, food additives and lifestyle products. Toxicol Lett.
258:S1792016. View Article : Google Scholar
|
|
12
|
Docea AO, Gofita E, Goumenou M, Calina D,
Rogoveanu O, Varut M, Olaru C, Kerasioti E, Fountoucidou P,
Taitzoglou I, et al: Six months exposure to a real life mixture of
13 chemicals' below individual NOAELs induced non monotonic
sex-dependent biochemical and redox status changes in rats. Food
Chem Toxicol. 115:470–481. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Docea AO, Goumenou M, Calina D, Arsene AL,
Dragoi CM, Gofita E, Pisoschi CG, Zlatian O, Stivaktakis PD,
Nikolouzakis TK, et al: Adverse and hormetic effects in rats
exposed for 12 months to low dose mixture of 13 chemicals: RLRS
part III. Toxicol Lett. 310:70–91. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fountoucidou P, Veskoukis AS, Kerasioti E,
Docea AO, Taitzoglou IA, Liesivuori J, Tsatsakis A and Kouretas D:
A mixture of routinely encountered xenobiotics induces both redox
adaptations and perturbations in blood and tissues of rats after a
long-term low-dose exposure regimen: The time and dose issue.
Toxicol Lett. 317:24–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsatsakis A, Petrakis D, Nikolouzakis TK,
Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis
C, Aschner M, et al: COVID-19, an opportunity to reevaluate the
correlation between long-term effects of anthropogenic pollutants
on viral epidemic/pandemic events and prevalence. Food Chem
Toxicol. In Press.
|
|
16
|
Han S: Clinical vaccine development. Clin
Exp Vaccine Res. 4:46–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamal AM, Mitrut P, Docea AO, Soşoi S,
Kamal KC, Mitrut R, Mărgăritescu D, Călina D, Banciu C, Tica OS, et
al: Double therapy with pegylated Interferon and Ribavirin for
chronic hepatitis C. A pharmacogenenetic guide for predicting
adverse events. Farmacia. 65:877–884. 2017.
|
|
18
|
Black S: The costs and effectiveness of
large Phase III pre-licensure vaccine clinical trials. Expert Rev
Vaccines. 14:1543–1548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wouters-Wesseling W, Rozendaal M, Snijder
M, Graus Y, Rimmelzwaan G, De Groot L and Bindels J: Effect of a
complete nutritional supplement on antibody response to influenza
vaccine in elderly people. J Gerontol A Biol Sci Med Sci.
57:M563–M566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsoukalas D, Fragkiadaki P, Docea AO,
Alegakis AK, Sarandi E, Vakonaki E, Salataj E, Kouvidi E, Nikitovic
D, Kovatsi L, et al: Association of nutraceutical supplements with
longer telomere length. Int J Mol Med. 44:218–226. 2019.PubMed/NCBI
|
|
21
|
Ventura MT, Casciaro M, Gangemi S and
Buquicchio R: Immunosenescence in aging: Between immune cells
depletion and cytokines up-regulation. Clin Mol Allergy. 15:212017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Savy M, Edmond K, Fine PE, Hall A, Hennig
BJ, Moore SE, Mulholland K, Schaible U and Prentice AM: Landscape
analysis of interactions between nutrition and vaccine responses in
children. J Nutr. 139:2154S–2218S. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arvas A: Vaccination in patients with
immunosuppression. Turk Pediatri Ars. 49:181–185. 2014. View Article : Google Scholar
|
|
24
|
Pickering LK, Baker CJ, Kimberlin DW and
Long SS: Red Book: 2012 Report of the Committee on Infectious
Diseases.
|
|
25
|
Keusch GT: Nutritional effects on response
of children in developing countries to respiratory tract pathogens:
Implications for vaccine development. Rev Infect Dis. 13(Suppl 6):
S486–S491. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Opal SM, Girard TD and Ely EW: The
immunopathogenesis of sepsis in elderly patients. Clin Infect Dis.
41(Suppl 7): S504–S512. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eliakim A, Schwindt C, Zaldivar F, Casali
P and Cooper DM: Reduced tetanus antibody titers in overweight
children. Autoimmunity. 39:137–141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calina D, Roșu L, Roșu AF, Ianoşi G,
Ianoşi S, Zlatian O, Mitruț R, Docea AO, Rogoveanu O, Mitruț P, et
al: Etiological diagnosis and pharmacotherapeutic management of
parap-neumonic pleurisy. Farmacia. 64:946–952. 2016.
|
|
29
|
Skalny AV, Rink L, Ajsuvakova OP, Aschner
M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos
DA, Aaseth J, et al: Zinc and respiratory tract infections:
Perspectives for COVID-19 (Review). Int J Mol Med. 46:17–26.
2020.
|
|
30
|
Stanberry LR and Strugnell R: Vaccines of
the future. Understanding Modern Vaccines: perspectives in
Vaccinology. Garçon N, Stern PL and Cunningham AL: Elsevier; pp.
151–199. 2011
|
|
31
|
Scharf SF: Orphan drugs: The question of
products liability. Am J Law Med. 10:491–513. 1985.PubMed/NCBI
|
|
32
|
Haffner ME and Kelsey JV: Evaluation of
orphan products by the U.S. Food and Drug Administration. Int J
Technol Assess Health Care. 8:647–657. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Olliario P: Will the fight against
tropical diseases benefit from orphan drug status? Trop Med Int
Health. 2:113–115. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mahoney RT and Maynard JE: The
introduction of new vaccines into developing countries. Vaccine.
17:646–652. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Milstien J, Batson A and Meaney W: A
systematic method for evaluating the potential viability of local
vaccine producers. Vaccine. 15:1358–1363. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franceschi C, Salvioli S, Garagnani P, de
Eguileor M, Monti D and Capri M: Immunobiography and the
heterogeneity of immune responses in the elderly: A focus on
inflamation and trained immunity. Front Immunol. 8:9822017.
View Article : Google Scholar
|
|
37
|
DeStefano F, Bodenstab HM and Offit PA:
Principal controversies in vaccine safety in the United States.
Clin Infect Dis. 69:726–731. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pronker ES, Weenen TC, Commandeur H,
Claassen EH and Osterhaus AD: Risk in vaccine research and
development quantified. PLoS One. 8:e577552013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goetz KB, Pfleiderer M and Schneider CK:
First-in-human clinical trials with vaccines - what regulators
want. Nat Biotechnol. 28:910–916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guerra Mendoza Y, Garric E, Leach A,
Lievens M, Ofori-Anyinam O, Pirçon JY, Stegmann JU, Vandoolaeghe P,
Otieno L, Otieno W, et al: Safety profile of the RTS, S/AS01
malaria vaccine in infants and children: Additional data from a
phase III randomized controlled trial in sub-Saharan Africa. Hum
Vaccin Immunother. 15:2386–2398. 2019. View Article : Google Scholar :
|
|
41
|
Peeples L: News feature: Avoiding pitfalls
in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci USA.
117:8218–8221. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schlake T, Thess A, Fotin-Mleczek M and
Kallen KJ: Developing mRNA-vaccine technologies. RNA Biol.
9:1319–1330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yi Y, Lagniton PNP, Ye S, Li E and Xu RH:
COVID-19: What has been learned and to be learned about the novel
coronavirus disease. Int J Biol Sci. 16:1753–1766. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wojda TR, Valenza PL, Cornejo K, McGinley
T, Galwankar SC, Kelkar D, Sharpe RP, Papadimos TJ and Stawicki SP:
The Ebola Outbreak of 2014-2015: From Coordinated Multilateral
Action to Effective Disease Containment, Vaccine Development, and
Beyond. J Glob Infect Dis. 7:127–138. 2015. View Article : Google Scholar
|
|
45
|
Grenham A and Villafana T: Vaccine
development and trials in low and lower-middle income countries:
Key issues, advances and future opportunities. Hum Vaccin
Immunother. 13:2192–2199. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mazur NI, Higgins D, Nunes MC, Melero JA,
Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS,
Englund JA, et al: Respiratory Syncytial Virus Network (ReSViNET)
Foundation: The respiratory syncytial virus vaccine landscape:
Lessons from the graveyard and promising candidates. Lancet Infect
Dis. 18:e295–e311. 2018. View Article : Google Scholar
|
|
47
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI
|
|
48
|
Goumenou M, Spandidos DA and Tsatsakis A:
[Editorial] Possibility of transmission through dogs being a
contributing factor to the extreme Covid-19 outbreak in North
Italy. Mol Med Rep. 21:2293–2295. 2020.PubMed/NCBI
|
|
49
|
Chen Y, Liu Q and Guo D: Emerging
coronaviruses: Genome structure, replication, and pathogenesis. J
Med Virol. 92:418–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang P and Wang X: COVID-19: A new
challenge for human beings. Cell Mol Immunol. 17:555–557. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Q, Zhang Y, Wu L, Niu S, Song C,
Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al: Structural and
functional basis of SARS-CoV-2 entry by using human ACE2. Cell. Apr
7–2020.Epub ahead of print.
|
|
53
|
Li Y, Zhou W, Yang L and You R:
Physiological and pathological regulation of ACE2, the SARS-CoV-2
receptor. Pharmacol Res. 157:1048332020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lukassen S, Chua RL, Trefzer T, Kahn NC,
Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, et
al: SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in
bronchial transient secretory cells. EMBO J. 4:e1051142020.
|
|
55
|
Leung JM, Yang CX, Tam A, Shaipanich T,
Hackett TL, Singhera GK, Dorscheid DR and Sin DD: ACE-2 expression
in the small airway epithelia of smokers and COPD patients:
Implications for COVID-19. Eur Respir J. Apr 8–2020.Epub ahead of
print. View Article : Google Scholar
|
|
56
|
Mousavizadeh L and Ghasemi S: Genotype and
phenotype of COVID-19: Their roles in pathogenesis. J Microbiol
Immunol. Mar 31–2020.Epub ahead of print.
|
|
57
|
Woo PC, Huang Y, Lau SK and Yuen KY:
Coronavirus genomics and bioinformatics analysis. Viruses.
2:1804–1820. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu W, Fontanet A, Zhang PH, Zhan L, Xin
ZT, Baril L, Tang F, Lv H and Cao WC: Two-year prospective study of
the humoral immune response of patients with severe acute
respiratory syndrome. J Infect Dis. 193:792–795. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ganji A, Farahani I, Khansarinejad B,
Ghazavi A and Mosayebi G: Increased expression of CD8 marker on
T-cells in COVID-19 patients. Blood Cells Mol Dis. 83:1024372020.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Farsalinos K, Niaura R, Le Houezec J,
Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A and Poulas K:
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of
the nicotinic cholinergic system. Toxicol Rep. Apr 30–2020.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou G and Zhao Q: Perspectives on
therapeutic neutralizing antibodies against the Novel Coronavirus
SARS-CoV-2. Int J Biol Sci. 16:1718–1723. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kikkert M: Innate immune evasion by human
respiratory RNA viruses. J Innate Immun. 12:4–20. 2020. View Article : Google Scholar :
|
|
63
|
Jackson NAC, Kester KE, Casimiro D,
Gurunathan S and DeRosa F: The promise of mRNA vaccines: A biotech
and industrial perspective. NPJ Vaccines. 5:112020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang C, Maruggi G, Shan H and Li J:
Advances in mRNA Vaccines for infectious diseases. Front Immunol.
10:5942019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pardi N, Hogan MJ, Porter FW and Weissman
D: mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov.
17:261–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Maruggi G, Zhang C, Li J, Ulmer JB and Yu
D: mRNA as a transformative technology for vaccine development to
control infectious diseases. Mol Ther. 27:757–772. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kramps T and Probst J: Messenger RNA-based
vaccines: Progress challenges, applications. Wiley Interdiscip Rev
RNA. 4:737–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
World Health Organization (WHO): DRAFT
landscape of COVID-19 candidate vaccines. WHO; Geneva: 2020,
https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1.
Accessed April 11 2020.
|
|
69
|
Li L and Petrovsky N: Molecular mechanisms
for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines.
15:313–329. 2016. View Article : Google Scholar :
|
|
70
|
Hobernik D and Bros M: DNA Vaccines-How
Far From Clinical Use? Int J Mol Sci. 19:E36052018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ferraro B, Morrow MP, Hutnick NA, Shin TH,
Lucke CE and Weiner DB: Clinical applications of DNA vaccines:
Current progress. Clin Infect Dis. 53:296–302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Thanh Le T, Andreadakis Z, Kumar A, Gómez
Román R, Tollefsen S, Saville M and Mayhew S: The COVID-19 vaccine
development landscape. Nat Rev Drug Discov. Apr 9–2020.Epub ahead
of print. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
US National Library of Medicine,
ClinicalTrials.gov: A Study of a Candidate COVID-19 Vaccine
(COV001). https://clinicaltrials.gov/ct2/show/NCT04324606.
Accessed March 27 2020.
|
|
74
|
Clinical Trials Arena: University of
Oxford starts enrolment for Covid-19 vaccine trial. https://www.clinicaltrialsarena.com/news/oxford-university-covid-19-vaccine-trial/
Accessed March 30, 2020.
|
|
75
|
Clinical Trials Arena: Inovio commences
Phase I trial of DNA vaccine for Covid-19. https://www.clinicaltrialsarena.com/news/inovio-SARS-COV-2-vaccine-trial/.
Accessed April 7, 2020.
|
|
76
|
Zhang N, Tang J, Lu L, Jiang S and Du L:
Receptor-binding domain-based subunit vaccines against MERS-CoV.
Virus Res. 202:151–159. 2015. View Article : Google Scholar :
|
|
77
|
Lee NH, Lee JA, Park SY, Song CS, Choi IS
and Lee JB: A review of vaccine development and research for
industry animals in Korea. Clin Exp Vaccine Res. 1:18–34. 2012.
View Article : Google Scholar
|
|
78
|
Wang M, Jiang S and Wang Y: Recent
advances in the production of recombinant subunit vaccines in
Pichia pastoris. Bioengineered. 7:155–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Choi Y and Chang J: Viral vectors for
vaccine applications. Clin Exp Vaccine Res. 2:97–105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sarkar B, Islam SS, Zohora US and Ullah
MA: Virus like particles - A recent advancement in vaccine
development. Korean J Microbiol. 55:327–343. 2019.
|
|
81
|
Huang X, Wang X, Zhang J, Xia N and Zhao
Q: Escherichia coli-derived virus-like particles in vaccine
development. NPJ Vaccines. 2:32017. View Article : Google Scholar :
|
|
82
|
Sridhar S, Brokstad KA and Cox RJ:
Influenza vaccination strategies: Comparing inactivated and live
attenuated influenza vaccines. Vaccines (Basel). 3:373–389. 2015.
View Article : Google Scholar
|
|
83
|
Lauring AS, Jones JO and Andino R:
Rationalizing the development of live attenuated virus vaccines.
Nat Biotechnol. 28:573–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
US National Library of Medicine,
ClinicalTrials.gov: Immunity and Safety of Covid-19 Synthetic
Minigene Vaccine. https://clinicaltrials.gov/ct2/show/NCT04276896.
Accessed February 19, 2020.
|
|
85
|
US National Library of Medicine,
ClinicalTrials.gov: Safety and Immunity of Covid-19 aAPC Vaccine.
https://clinicaltrials.gov/ct2/show/NCT04299724.
Accessed March 9, 2020.
|
|
86
|
Dang-Tan T, Mahmud SM, Puntoni R and
Franco EL: Polio vaccines, Simian Virus 40, and human cancer: The
epidemiologic evidence for a causal association. Oncogene.
23:6535–6540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Strickler HD, Rosenberg PS, Devesa SS,
Hertel J, Fraumeni JF Jr and Goedert JJ: Contamination of
poliovirus vaccines with simian virus 40 (1955-1963) and subsequent
cancer rates. JAMA. 279:292–295. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Baylis SA, Finsterbusch T, Bannert N,
Blümel J and Mankertz A: Analysis of porcine circovirus type 1
detected in Rotarix vaccine. Vaccine. 29:690–697. 2011. View Article : Google Scholar
|
|
89
|
Smatti MK, Al Thani AA and Yassine HM:
Viral-induced enhanced disease illness. Front Microbiol.
9:29912018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tetro JA: Is COVID-19 receiving ADE from
other coronaviruses? Microbes Infect. 22:72–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xu J, Jia W, Wang P, Zhang S, Shi X, Wang
X and Zhang L: Antibodies and vaccines against Middle East
respiratory syndrome coronavirus. Emerg Microbes Infect. 8:841–856.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Colgrove J: Immunity for the people: The
challenge of achieving high vaccine coverage in American history.
Public Health Rep. 122:248–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lord JM: The effect of ageing of the
immune system on vaccination responses. Hum Vaccin Immunother.
9:1364–1367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Boda D, Docea AO, Calina D, Ilie MA,
Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE,
Voiculescu V, et al: Human papilloma virus: Apprehending the link
with carcinogenesis and unveiling new research avenues (Review).
Int J Oncol. 52:637–655. 2018.PubMed/NCBI
|
|
95
|
Wiedermann U, Garner-Spitzer E and Wagner
A: Primary vaccine failure to routine vaccines: Why and what to do?
Hum Vaccin Immunother. 12:239–243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Leitner WW, Ying H and Restifo NP: DNA and
RNA-based vaccines: Principles, progress and prospects. Vaccine.
18:765–777. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fehr AR and Perlman S: Coronaviruses: An
overview of their replication and pathogenesis. Methods Mol Biol.
1282:1–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Perlman S and Netland J: Coronaviruses
post-SARS: Update on replication and pathogenesis. Nat Rev
Microbiol. 7:439–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vandamme TF: Use of rodents as models of
human diseases. J Pharm Bioallied Sci. 6:2–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Fogel DB: Factors associated with clinical
trials that fail and opportunities for improving the likelihood of
success: A review. Contemp Clin Trials Commun. 11:156–164. 2018.
View Article : Google Scholar : PubMed/NCBI
|
